Emany Sravan Kumar 4

What Happened

• Emany Sravan Kumar, Chief Financial Officer of Beam Therapeutics (BEAM), was granted 31,750 restricted stock units (RSUs) on 2026-03-31. The award is reported as an acquisition at $0.00 per unit and represents a contingent right to receive one share of BEAM common stock for each RSU.
• This is an equity compensation grant (award), not an open-market purchase or sale; the RSUs vest in four substantially equal installments on each of the first four anniversaries of the grant, subject to continued service.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02.
• Transaction type/code: Grant / Award (A); 31,750 RSUs; acquisition price $0.00.
• Vesting: Four substantially equal annual installments beginning on the first anniversary of the grant (per footnote F1).
• Shares owned after transaction: Not specified in the supplied filing excerpt.
• Filing timeliness: Filed within the normal Form 4 reporting window (no late filing indicated).
• Footnote: F1 explains each RSU equals the contingent right to one share and reiterates the four-year vesting schedule.

Context

• RSU grants are a common form of executive compensation and do not represent an immediate market purchase or sale. The shares are typically issued to the executive only as RSUs vest (subject to service and any plan conditions).
• Such awards inform about company compensation practices but do not, by themselves, indicate the insider’s personal view on the stock.